Business
Integra LifeSciences Announces Preliminary Fourth Quarter and Full-Year 2019 Revenue Results and 2020 Financial Guidance
Fourth quarter 2019 reported revenue is expected to be at or near the low end of the previously communicated guidance range of $395 to $400 million,
About this update from Integra Lifesciences Holdings Corporation
[{"type":"text","content":"Fourth quarter 2019 reported revenue is expected to be at or near the low end of the previously communicated guidance range of $395 to $400 million, representing organic revenue growth of slightly less than 5% and reported growth of approximately 3%;For the full-year 2020, the company is providing preliminary revenue guidance in the range of $1,550 million to $1,570 million, representing organic revenue growth of approximately 5% and reported growth of approximately 3%;For the full-year 2020, the company is providing preliminary guidance of double-digit earnings per share growth compared to the full-year 2019;The company plans to implement a share repurchase program that was previously approved by the Board of Directors, with an authorization of up to $225 million. PLAINSBORO, N.J., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fourth quarter and full-year 2019 financial results.\n Preliminary Fourth Quarter and Full-Year 2019 Revenue Results Fourth quarter 2019 reported revenue is expected to be at or near the low end of the previously communicated guidance range of $395 million to $400 million, representing organic revenue growth of slightly less than 5% and reported growth of approximately 3%. As a result of its fourth quarter preliminary results, the company expects full-year 2019 reported revenue to be at or near the low end of the previously communicated guidance range of $1,517 million to $1,522 million, representing organic growth of slightly less than 5% and reported growth of approximately 3%. The preliminary results set forth above are unaudited and remain subject to completion of the Company’s financial closing procedures. Preliminary 2020 Financial Guidance The company expects full-year 2020 reported revenue to be in the range of $1,550 million to $1,570 million, representing organic revenue growth of approximately 5% and reported growth of approximately 3%. The company expects full-year 2020 earnings per share to increase double digits compared to the full-year 2019. Share Repurchase Program The company plans to implement a share repurchase program, previously approved by the Board of Directors, with an authorization of up to $225 million. The company may repurchase shares from ti...